Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-02-14 1:59 pm Sale | 2024-12-31 | 13G | Inozyme Pharma, Inc. INZY | Samlyn Capital, LLC | 0 0.000% | -3,372,558 (Position Closed) | Filing History |
| 2024-12-09 4:14 pm Purchase | 2024-12-02 | 13G | Inozyme Pharma, Inc. INZY | Affinity Asset Advisors LLC | 3,972,318 6.180% | 3,972,318 (New Position) | Filing History |
| 2024-11-14 12:19 pm Purchase | 2024-09-30 | 13G | Inozyme Pharma, Inc. INZY | Eventide Asset Management, LLC | 4,134,436 6.440% | 954,599 (+30.02%) | Filing History |
| 2024-11-08 2:17 pm Unchanged | 2024-09-30 | 13G | Inozyme Pharma, Inc. INZY | BlackRock Inc. BLK | 3,491,236 5.600% | 0 (Unchanged) | Filing History |
| 2024-10-24 2:02 pm Purchase | 2024-09-30 | 13G | Inozyme Pharma, Inc. INZY | BlackRock Inc. BLK | 3,491,236 5.600% | 3,491,236 (New Position) | Filing History |
| 2024-02-20 7:11 pm Purchase | 2023-07-28 | 13D | Inozyme Pharma, Inc. INZY | Sofinnova Venture Partners X L.P. | 4,280,308 6.900% | 2,252,000 (+111.03%) | Filing History |
| 2024-02-14 8:34 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Venrock Healthcare Capital Partners II, L.P. | 0 0.000% | -3,867,749 (Position Closed) | Filing History |
| 2024-02-14 6:08 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | New Enterprise Associates 15 L.P. | 0 0.000% | -2,437,689 (Position Closed) | Filing History |
| 2024-02-14 4:21 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Baker Bros. Advisors LP | 0 0.000% | -2,168,000 (Position Closed) | Filing History |
| 2024-02-14 2:10 pm Purchase | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Rock Springs Capital Management LP | 3,681,174 5.960% | 595,147 (+19.29%) | Filing History |
| 2024-02-14 1:40 pm Purchase | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Samlyn Capital, LLC | 3,372,558 5.500% | 3,372,558 (New Position) | Filing History |
| 2024-02-14 11:54 am Purchase | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Eventide Asset Management, LLC | 3,179,837 5.150% | 3,179,837 (New Position) | Filing History |
| 2024-02-14 08:48 am Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | Deep Track Capital, LP | 0 0.000% | -3,250,000 (Position Closed) | Filing History |
| 2024-02-12 9:06 pm Unchanged | 2024-02-12 | 13D | Inozyme Pharma, Inc. INZY | Pivotal bioVenture Partners Fund I L.P. | 4,494,851 7.200% | 0 (Unchanged) | Filing History |
| 2024-02-07 07:46 am Purchase | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | ADAGE CAPITAL PARTNERS GP L.L.C. | 5,537,500 8.970% | 2,437,362 (+78.62%) | Filing History |
| 2024-02-05 09:12 am Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | SPHERA FUNDS MANAGEMENT LTD. | 1,562,907 2.530% | -533,351 (-25.44%) | Filing History |
| 2024-01-16 4:12 pm Sale | 2023-12-31 | 13G | Inozyme Pharma, Inc. INZY | MILLENNIUM MANAGEMENT LLC | 911,465 1.500% | -1,381,362 (-60.25%) | Filing History |
| 2023-08-11 4:08 pm Purchase | 2023-08-01 | 13D | Inozyme Pharma, Inc. INZY | Longitude Capital Partners III LLC | 5,841,045 9.900% | 1,666,666 (+39.93%) | Filing History |
| 2023-08-07 9:58 pm Purchase | 2023-08-01 | 13D | Inozyme Pharma, Inc. INZY | Pivotal bioVenture Partners Fund I L.P. | 4,494,851 9.500% | 833,333 (+22.76%) | Filing History |
| 2023-05-31 4:17 pm Purchase | 2023-05-22 | 13G | Inozyme Pharma, Inc. INZY | MILLENNIUM MANAGEMENT LLC | 2,292,827 5.200% | 2,292,827 (New Position) | Filing History |